BKYI

BIO-key sells a genuinely differentiated product — a NIST/FBI-certified biometric IAM platform (PortalGuard) with one bank identifying 21.7M customers daily via its fingerprint tech, and software-grade 76.9% gross margins. But a good product wrapped in a broken financial model is not a stock. Revenue fell 14.3% to $5.94M in FY2025, and the MD&A shows why the decline is structural, not a blip: license fees (the highest-margin line) collapsed 34% because a foreign retail-bank renewal that padded 2024 did not recur, and the company is simultaneously absorbing its exit from the Swivel Secure distribution deal as it re-launches EMEA selling only BIO-key product. Hardware sales more than doubled (+112%), but that is the lowest-quality revenue and was partly juiced by selling off fully-reserved Nigerian project inventory — a one-time tailwind, not a growth engine.

The balance sheet is the disqualifier. Operating cash flow was -$4.67M in FY2025 against just $2.69M of cash — under a year of runway at the current burn, before any of the seasonal working-capital swings a lumpy license business throws off. Net loss widened 66% to -$7.16M, operating margin is -115%, ROE is -140%, and the accumulated deficit stands at -$136M against only $5.11M of book equity. This is a company that has never sustainably earned money and structurally consumes more cash than it holds. The 1-for-10 reverse stock split effective April 30, 2026 — which is why the share count reads 1.09M — is the tell: it is a mechanical maneuver to preserve a listing, and the near-certain sequel is another dilutive equity raise, since the cash simply is not there to fund the loss.